Evidence map›Paper›PMID 37376066›Full record

ArticlePharmaceutics2023

Biomimetic Theranostic Agents with Superior NIR-II Photoacoustic and Magnetic Resonance Imaging Performance for Targeted Photothermal Therapy of Prostate Cancer.

Ling Liu, Shangpo Yang, Ziliang Zheng, Qingshuang Li, Chenchen Liu, Dehong Hu, Zhou Liu, Xiaoping Zhang, Ruiping Zhang, Duyang Gao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Ling LiuDepartment of Radiology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China.
Shangpo YangPaul C. Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Ziliang ZhengDepartment of Radiology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China.
Qingshuang LiPaul C. Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Chenchen LiuDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
Dehong HuPaul C. Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Zhou LiuDepartment of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.
Xiaoping ZhangDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
Ruiping ZhangDepartment of Radiology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China.
Duyang GaoPaul C. Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Shenzhen Institutes of Advanced Technology · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese Academy of Sciences · CNFirst Hospital of Shanxi Medical University · CNHuazhong University of Science and Technology · CNShanxi Medical University · CNUnion Hospital · CN

Funding

CAS Key Laboratory of Health Informatics 2011DP173015Guangdong Basic and Applied Basic Research Fund 2023A1515010747 and 2022A1515010384Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province 2020B1212060051National Natural Science Foundation of China 81927807the Science and Technology Key Project of Shenzhen JCYJ20200109114612308, and JCYJ20210324120011030
6 · The paper itself

Abstract

The accurate diagnosis and treatment of prostate cancer at an early stage is crucial to reduce mortality rates. However, the limited availability of theranostic agents with active tumor-targeting abilities hinders imaging sensitivity and therapeutic efficiency. To address this challenge, we have developed biomimetic cell membrane-modified Fe

Indexed as

cancer therapymagnetic resonance imagingphotoacoustic imagingphotothermal therapytheranostic nanoparticlesthe second near-infrared window

Identifiers

PMID37376066
PMCPMC10305050
OpenAlexW4381463215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.